What are the limitations of the ipss m?

While the ipss m is highly validated, it should not replace clinical judgment. OpiCalc provides the latest evidence-based limitations for the ipss m to ensure safe bedside use and optimal diagnostic accuracy.

How does the ipss m compare to other Hematology scores?

The ipss m is a gold-standard diagnostic tool. OpiCalc provides side-by-side clinical guidance to help clinicians choose the most specific evidence-based tool for their patient's presentation.

Is the ipss m free to use?

Yes. OpiCalc provides the ipss m completely ad-free and optimized for mobile bedside use, ensuring you can calculate medical risk swiftly and without distraction.

OpiCalc

927 Clinical Tools

OpiCalc

4Ts Score (HIT)aaIPI (Age-adjusted IPI)ABC Score (Massive Transfusion)Absolute Neutrophil Count Age-adjusted D-dimer Threshold aGvHD Grading (Glucksberg/MAGIC)AL Amyloidosis Staging (Mayo)Anti-Xa Monitoring Interpreter Antiphospholipid Syndrome Classification Binet / Rai Staging (CML)Blood Volume Calculator Caprini VTE Risk CISNE Score CLL-IPI Coombs-Negative Haemolysis Checklist Corrected Reticulocyte Count CRS Grading (ASTCT 2019)DAT Interpretation Algorithm Deauville Score Interpreter DIC Score (ISTH)DIPSS (MF)DIPSS-Plus (MF)DOAC Dose Selector DOAC Renal Dose Adjustment DRI (Disease Risk Index)Durie-Salmon Staging (historical)EBMT Risk Score ELN 2022 AML Risk Classification ELTS Score (CML)England & Fraser Index EUTOS Score (CML)Expected Hb Rise per RBC Unit Factor Inhibitor Bethesda Titre Interpreter Febrile Neutropaenia Risk (MASCC)Fibrinogen Replacement FLIPI (Follicular Lymphoma IPI)FLIPI-2 French TTP Score GAPSS (Global APS Score)Haemophilia Severity Classification HbS Percentage Target Calculator HCT-CI (Comorbidity Index)HEP Score Heparin Nomogram (Weight-based)Hepatic Iron Index HERDOO2 Rule HFE Haemochromatosis Risk Estimator ICANS Grading (ASTCT 2019)IMWG Response Criteria (Myeloma)IPI (International Prognostic Index)IPSID / Lugano Classification IPSS-M (Molecular IPSS)IPSS-R (Revised IPSS for MDS)Iron Deficit Calculator (Ganzoni Formula)ISS (Myeloma)ISTH Bleeding Assessment Tool (BAT)ISTH Non-Overt DIC Score ITP Bleeding Score iwCLL Response Criteria (2018)IWG ITP Response Criteria JAK2V617F Allele Burden Interpreter Karnofsky Performance Scale Leucostasis Risk Threshold Lupus Anticoagulant (LAC) Reporting Framework MAGIC aGvHD Biomarker Score MCV-based Anaemia Algorithm Mentzer Index MIPI (MCL IPI)MIPSS70+ v2.0 (MF)Mixing Study Interpretation MRD Assessment Threshold Interpreter mSMART 3.0 (Myeloma)MTP Activation Criteria NCCN-IPI NIH Chronic GvHD Scoring NTDT Iron Burden Estimator Padua RAM PBT (Paediatric BAT)PCNSL MSKCC Score PERC Rule Perioperative Anticoagulation Bridging PESI Score (PE Mortality)PLASMIC Score Platelet Increment Calculator (CCI)PNH Clone Size Interpreter R-IPI (Revised IPI)R-ISS (Revised ISS)Reticulocyte Index (RPI)Revised Geneva Score (PE)Revised Response Criteria (NHL)Revised Zubrod / ECOG Performance Shine & Lal Index Sickle Cell Disease Risk (TCD)SLiM-CRAB Criteria SOKAL Score (CML)Sokal/EUTOS/ELTS Comparison sPESI (Simplified PESI)TACO Risk Score Thalassaemia Transfusion Threshold Thrombocytopaenia Differential Thrombophilia Screening Eligibility Algorithm Time in Therapeutic Range (TTR)TLS Risk Classification Transferrin Saturation Calculator Vienna Prediction Model von Willebrand Factor Activity Interpreter Warfarin Dose Calculator Wells Score (DVT)Wells Score (PE)WHO 2022 AML Classification Mapper WHO Bleeding Scale YEARS Algorithm

IPSS-M (Molecular IPSS)

IPSS-M Guide: High-level genomic risk stratification. Combines clinical parameters with NGS data. Note: Full IPSS-M calculation requires specialized algorithmic software; this tool highlights the prognostic impact of key genes.

TP53 Allelic State

Other Somatic Mutations

Molecular Risk Impact

Low/Genomic Stable

Favorable molecular profile (no adverse drivers identified).

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Refined risk stratification of MDS patients using both clinical and genomic (NGS) data.

Identifying patients with "molecularly high-risk" profile who may be under-scored by IPSS-R.

Predicting survival and AML transformation risk with 2022-standard precision.

Patient Population

Adult patients with newly diagnosed de novo MDS (matched to the Molecular IPSS database).

The "NGS" Requirement

The IPSS-M requires results from a myeloid mutation panel (typically 16-31 genes), including TP53 allelic state, SF3B1, and other common MDS mutations.

Section 2

Formula & Logic

Biological Integration

IPSS-M integrates 5 clinical features (blasts, Hb, PLT, ANC, cyto) with the somatic mutation status of 16 core genes and 15 additional features.

Key Genetic Drivers

TP53 (Multi-hit vs Single-hit): Multi-hit (biallelic) TP53 is the strongest adverse predictor.

MLL (KMT2A) rearrangements / PTPN11 / NRAS / KRAS / FLT3.

SF3B1: Historically associated with "Ring Sideroblasts" and better outcomes, unless associated with adverse mutations.

Section 3

Pearls/Pitfalls

Re-stratification Power

Approximately 46% of patients are re-stratified by IPSS-M compared to IPSS-R. Specifically, many "Intermediate" IPSS-R patients are moved to "High" once their molecular profile is added.

Section 4

Evidence Appraisal

Primary Score

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Bernard E et al. • NEJM Evidence. 2022;1(7). n=2,831 patients.

View Source

Section 5

Literature

Development

Developed by an international consortium led by the Memorial Sloan Kettering Cancer Center. It represents the "next generation" of MDS risk assessment, replacing purely morphological systems.

Last Comprehensive Review: 2026

Related Hematology Tools

Age-adjusted D-dimer Threshold

sPESI

HEP Score

HERDOO2 Rule

Vienna Prediction Model

Padua RAM

Antiphospholipid Syndrome Classification

GAPSS

Thrombophilia Screening Eligibility Algorithm

IPSS-R

Have feedback about this calculator?Let us know.